All In Biotech

Drug Trial Radar · NCT04319198

Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy

Open-label Rollover Study to Evaluate Long-Term Safety in Subjects With Metastatic Solid Tumors That Are Benefiting From Continuation of Therapy With Sacituzumab Govitecan

Last checked: Nov 20, 2026Latest source record: Sep 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

25

Actual

Start

Aug 4, 2020

Primary completion

Oct 18, 2024

Study completion Oct 18, 2024

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Mar 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and how safe it is in participants with metastatic cancer (cancer that has spread).

Conditions

  • Metastatic Solid Tumors

Interventions

  • Sacituzumab Govitecan-hiyDrug

    Administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Experiencing Any Adverse EventsTime frame: First dose date up to 30 days post last dose (Up to 3.9 years)
  2. Percentage of Participants Experiencing Any Serious Adverse EventsTime frame: First dose date up to 30 days post last dose (Up to 3.9 years)
  3. Percentage of Participants Experiencing Any Grade and Grade 3 or 4 Laboratory AbnormalitiesTime frame: First dose date up to 30 days post last dose (Up to 3.9 years)

Locations

21 sites in 3 countries. Site status is shown where the registry gives one.

  • University of California San Francisco

    San Francisco, California

  • Rocky Mountain Cancer Center

    Aurora, Colorado

  • Christiana Care Health Services, Christiana Hospital

    Newark, Delaware

  • Florida Cancer Specialists & Research Institute

    Fort Myers, Florida

  • Baptist Health - Miami Cancer Institute

    Miami, Florida

  • Illinois Cancer Specialists

    Arlington Heights, Illinois

  • University of Chicago

    Chicago, Illinois

  • University of MD Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • New York Cancer & Blood Specialists - Setauket Medical Oncology

    Port Jefferson, New York

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Next Oncology

    Austin, Texas

  • Oncology Consultants,P.A.

    Houston, Texas

  • The University of Texas M.D. Anderson Cancer Center

    Houston, Texas

  • NEXT Oncology

    San Antonio, Texas

  • Institut Jules Bordet

    Brussels, Belgium

  • CHU UCL NAMUR - Sainte Elisabeth

    Namur, Belgium

  • Institut Bergonie

    Bordeaux, France

  • Centre Leon Berard

    Lyon, France

  • Institut Claudius Regaud

    Toulouse, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.